Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Docetaxel, Oxaliplatin, Capecitabine plus Bevacizumab with Trastuzumab for HER2-positive Gastric or Gastro-oesophageal Junction Cancer
2010-022699-30Phase 2Active
- Sponsor
- Netherlands Cancer Institute
- Start
- Sep 2010
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel, oxaliplatin, capecitabine, bevacizumab and trastuzumab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Netherlands Cancer Institute. Primary endpoint: Progression-free survival. Started Sep 2010; status: active.
02
Drugs
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2010-022699-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022699-30.